Iradimed Corp. (NASDAQ: IRMD) reported Q1 EPS of $0.30, $0.02 better than the analyst estimate of $0.28. Revenue for the quarter came in at $15.5 million versus the consensus estimate of $14.85 million.

GUIDANCE:

Iradimed Corp. sees FY2023 EPS of $1.26-$1.35, versus the consensus of $1.32. Iradimed Corp. sees FY2023 revenue of $62-63.5 million, versus the consensus of $62.5 million.

For earnings history and earnings-related data on Iradimed Corp. (IRMD) click here.